Paid Clinical Trials in Topeka, KS
As of July 2026, 90 paid clinical trials are recruiting in Topeka, Kansas. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Topeka offers studies at sites including University of Kansas Health System Saint Francis Campus for conditions such as Obesity, Overweight, Anatomic Stage II Breast Cancer AJCC v8, Crohn Disease. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Topeka
Trials by drug in Topeka
Filter results
Newly added in Topeka
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
88 clinical trials
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Family Communications After Genetic Testing
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Top Research Study Locations in Topeka
Researchers run research studies in Topeka, KS at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| University of Kansas Health System Saint Francis Campus | Anatomic Stage II Breast Cancer AJCC v8, Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm | 43 |
| Cotton O'Neil Cancer Center / Stormont Vail Health | Acute Myeloid Leukemia, Melanoma, Acute Lymphoblastic Leukemia | 10 |
| Cotton O'Neil Diabetes & Endocrinology | Obesity, Overweight, Diabetes Mellitus, Type 2 | 6 |
| Cotton O'Neil Digestive Health Center | Colitis, Ulcerative, Crohn Disease, Metabolic Dysfunction-Associated Steatotic Liver Disease | 5 |
| GSK Investigational Site | Non-alcoholic Fatty Liver Disease, Chickenpox, Liver Diseases, Alcoholic | 4 |
| Cotton O'Neil Clinical Research Center | Obesity, Overweight, Chronic Obstructive Pulmonary Disease (COPD) | 3 |
| 89bio Clinical Study Site | Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis | 2 |
| Akero Clinical Study Site | MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASH With Fibrosis, NASH - Nonalcoholic Steatohepatitis | 2 |
| Clinical Trial Site | High Cardiovascular Risk, High Risk Cardiovascular Disease, Hypertension | 1 |
| Cotton O Neil Clinical Res Center | Cardiovascular Disease and Lipoprotein(a) | 1 |
| Cotton O'Neil Cancer Center | Diffuse Large B-Cell Lymphoma | 1 |
| Cotton O'Neil Clinical Research Center - 1151 | Non Small Cell Lung Cancer | 1 |
| Cotton O'Neil Diab & Endo Ctr | Obesity, Type 2 Diabetes | 1 |
| Cotton O'Neil Diabetes & Endocrinology Center | Cardiovascular Diseases, Diabetes Mellitus, Type 2, Hypertension | 1 |
| Cotton O'Neil Research Center | Pneumococcal Infection | 1 |
| Cotton ONeil Clinical Research Center | Crohn's Disease | 1 |
| Cotton-O'Neil Clinical Research Center | Crohn Disease | 1 |
| Cotton-ONeil Diabetes and Endocrinology Center | Atherosclerotic Cardiovascular Disease, Obesity, Overweight | 1 |
| Home-based telemedicine | Chronic Granulomatous Disease (CGD) | 1 |
| KUCC MCA- TUKHS, Saint Francis Hospital | Non Small Cell Lung Cancer Stage | 1 |
| Kansas Medical Clinic PA | Liver Fibrosis, Metabolic Dysfunction Associated Steatohepatitis (MASH) | 1 |
| Research | Hypertriglyceridemia | 1 |
| Topeka VA Hospital | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma | 1 |
| University of Kansas Health System St. Francis Campus | Lumbar Spinal Stenosis | 1 |
| VA Eastern Kansas Healthcare System | Cardiovascular Diseases, Cognitive Impairment, Mild, Dementia | 1 |
Active & Upcoming Studies in Topeka (2026)
Recruiting trials in Topeka grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (49 active studies)
- Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL · Phase 3 · Alliance for Clinical Trials in Oncology
- Family Communications After Genetic Testing · Alliance for Clinical Trials in Oncology
Diabetes & metabolic (16 active studies)
- A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes · Phase 3 · Eli Lilly and Company
- A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes · Phase 2 · Novo Nordisk A/S
Mental health & behavior (2 active studies)
- E-Mindfulness Approaches for Living After Breast Cancer · Phase 3 · NRG Oncology
- Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program · Phase 3 · Alliance for Clinical Trials in Oncology
Cardiovascular (2 active studies)
- Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease · Phase 3 · Alnylam Pharmaceuticals
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease · Phase 3 · Boehringer Ingelheim
Neurology & pain (1 active study)
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO · Phase 1 · National Cancer Institute (NCI)
Common conditions studied in Topeka
- Obesity (7 active studies)
- Overweight (6 active studies)
- Anatomic Stage II Breast Cancer AJCC v8 (4 active studies)
- Crohn Disease (4 active studies)
- Lung Non-Small Cell Carcinoma (4 active studies)
- Malignant Solid Neoplasm (4 active studies)
Leading research sponsors in Topeka
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
- NRG Oncology
- SWOG Cancer Research Network
- Eli Lilly and Company
Frequently asked questions
How many paid clinical trials are currently recruiting in Topeka?
There are approximately 90 recruiting clinical trials in Topeka, Kansas listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Topeka pay participants?
Most recruiting trials in Topeka compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Topeka?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Topeka?
The most common conditions under active study in Topeka include Obesity (7), Overweight (6), Anatomic Stage II Breast Cancer AJCC v8 (4), Crohn Disease (4), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Topeka?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Topeka on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Topeka?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Topeka?
Recruiting research sites in Topeka include University of Kansas Health System Saint Francis Campus, Cotton O'Neil Cancer Center / Stormont Vail Health, Cotton O'Neil Diabetes & Endocrinology, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Topeka right now?
The largest active categories in Topeka are Cancer & tumors (49), Diabetes & metabolic (16), Mental health & behavior (2). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.